Being commonly abbreviated as D5N (where "lima" is the Indonesian word for "five"), this parent company was first established in 1989 due to the
collaboration between Lima November University (which belongs to the same foundation as Lima November High School), Delta Pharma, and St. Hermione Hospital as the official research hospital — in order to develop then-upcoming Tombocantuxin
caffeine pills (scheduled to launch by 1990). After enjoying the successfulness of Tombocantuxin caffeine pills, in the late 1990's the conglomeracy D5N (Delta Lima November) which also doubles as a research institute, now had the next project of researching the benefits and negative effects of screen time on children and youth. By 2005, this eventually led to the launch of the injectional drug treatment meant to cure
internet addiction called Ecrantemp, after the French phrase "temps d'ecran" (meaning "screen time").